Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Fortress Biotech (FBIO) over the last 8 years, with Q3 2025 value amounting to $737132.0.

  • Fortress Biotech's Gains from Sales and Divestitures rose 61894.98% to $737132.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $737132.0, marking a year-over-year increase of 61894.98%. This contributed to the annual value of $137655.0 for FY2024, which is 2429.51% down from last year.
  • Per Fortress Biotech's latest filing, its Gains from Sales and Divestitures stood at $737132.0 for Q3 2025, which was up 61894.98% from $152585.0 recorded in Q2 2025.
  • Fortress Biotech's 5-year Gains from Sales and Divestitures high stood at $1.8 million for Q4 2022, and its period low was $17206.0 during Q1 2024.
  • For the 5-year period, Fortress Biotech's Gains from Sales and Divestitures averaged around $346647.4, with its median value being $236668.0 (2021).
  • As far as peak fluctuations go, Fortress Biotech's Gains from Sales and Divestitures plummeted by 9434.71% in 2024, and later skyrocketed by 61894.98% in 2025.
  • Quarter analysis of 5 years shows Fortress Biotech's Gains from Sales and Divestitures stood at $712449.0 in 2021, then surged by 146.42% to $1.8 million in 2022, then crashed by 89.64% to $181831.0 in 2023, then dropped by 24.3% to $137655.0 in 2024, then surged by 435.49% to $737132.0 in 2025.
  • Its Gains from Sales and Divestitures was $737132.0 in Q3 2025, compared to $152585.0 in Q2 2025 and $77124.0 in Q1 2025.